Rene S. Bermea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rene S. Bermea has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Synn
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA, USA
3 shared publications Barry S. Shea
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3 shared publications- Bess M. Flashner
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
3 shared publications Julia K. Munchel
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
3 shared publications- Mary Berlik Rice
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, MA, USA
3 shared publications Fiona K. Gibbons
Harvard Medical School, Boston, MA, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
2 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (1) , 2501638
Low forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease
Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.
- 5 December 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 67 (1) , 2501638
Open AccessLow forced vital capacity is associated with poor prognosis in physiologically stable non-IPF interstitial lung disease
Current guidelines define progressive pulmonary fibrosis (PPF) as the presence of at least two of the following three changes within 12 months: worsening symptoms, lung function decline, or new/extending radiographic abnormalities [1, 2]. However, limiting assessment to subsequent progression may miss high-risk patients: those presenting with severely impaired lung function may meet none of the criteria if later tests remain unchanged, delaying therapy initiation and close monitoring. Therefore, we examined whether baseline forced vital capacity (FVC) was associated with an increased risk of lung transplantation or death in non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung disease (ILD) patients whose FVC declined by <5 percentage points predicted during the first year after diagnosis.
- Open Access
- 23 June 2025
- Published by Association for Computing Machinery (ACM)
- p. 1450-1467
Lost in Transplantation: Characterizing Racial Gaps in Physician Organ Offer Acceptance
- 23 June 2025
- Published by Association for Computing Machinery (ACM)
- p. 1450-1467
Open AccessLost in Transplantation: Characterizing Racial Gaps in Physician Organ Offer Acceptance
- 13 May 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 88, 101176
Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD
- 13 May 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 88, 101176
Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD
- Open Access
- 4 April 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 87, 101170
Progressive course of anti-nuclear matrix protein-2 (NXP-2) positive-interstitial lung disease
- 4 April 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 87, 101170
Open AccessProgressive course of anti-nuclear matrix protein-2 (NXP-2) positive-interstitial lung disease
- 29 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (783) , eads1298
Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease
Tissue-specific T cell immune responses play a critical role in maintaining organ health but can also drive immune pathology during both autoimmunity and alloimmunity. The mechanisms controlling intratissue T cell programming remain unclear. Here, we leveraged a nonhuman primate model of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation to probe the biological underpinnings of tissue-specific alloimmune disease using a comprehensive systems immunology approach including multiparameter flow cytometry, population-based transcriptional profiling, and multiplexed single-cell RNA sequencing and TCR sequencing. Transcriptional profiling revealed substantial biological differences between T cells infiltrating the lung and liver during aGVHD. These included enrichment for transcriptional pathways controlling extracellular matrix remodeling and chemotaxis in the lung and enrichment for transcriptional pathways linked to nucleic acid metabolism and proliferation in the liver. Single-cell RNA sequencing and TCR sequencing substantiated divergent organ-specific transcriptional programing of tissue-infiltrating T cells, which was linked to clonal expansion, with expanded clones progressively enriched for C-X3-C motif chemokine receptor 1 ( CX3CR1 )–expressing CD8 effector T cells in the lung and eomesodermin ( EOMES )–expressing CD8 effector-memory T cells in the liver. This divergent evolution of T cells was maintained even for T cells sharing the same TCRs, indicating its independence from antigen specificity. Together, these results provide insights into the role that tissue microenvironment–derived signals play in local T cell transcriptional programming during alloimmune-mediated clonal expansion and suggest potential opportunities to develop tissue-specific therapeutics to curtail pathogenic immunity after transplant.
- 29 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (783) , eads1298
Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease
Tissue-specific T cell immune responses play a critical role in maintaining organ health but can also drive immune pathology during both autoimmunity and alloimmunity. The mechanisms controlling intratissue T cell programming remain unclear. Here, we leveraged a nonhuman primate model of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation to probe the biological underpinnings of tissue-specific alloimmune disease using a comprehensive systems immunology approach including multiparameter flow cytometry, population-based transcriptional profiling, and multiplexed single-cell RNA sequencing and TCR sequencing. Transcriptional profiling revealed substantial biological differences between T cells infiltrating the lung and liver during aGVHD. These included enrichment for transcriptional pathways controlling extracellular matrix remodeling and chemotaxis in the lung and enrichment for transcriptional pathways linked to nucleic acid metabolism and proliferation in the liver. Single-cell RNA sequencing and TCR sequencing substantiated divergent organ-specific transcriptional programing of tissue-infiltrating T cells, which was linked to clonal expansion, with expanded clones progressively enriched for C-X3-C motif chemokine receptor 1 ( CX3CR1 )–expressing CD8 effector T cells in the lung and eomesodermin ( EOMES )–expressing CD8 effector-memory T cells in the liver. This divergent evolution of T cells was maintained even for T cells sharing the same TCRs, indicating its independence from antigen specificity. Together, these results provide insights into the role that tissue microenvironment–derived signals play in local T cell transcriptional programming during alloimmune-mediated clonal expansion and suggest potential opportunities to develop tissue-specific therapeutics to curtail pathogenic immunity after transplant.
- Open Access
Lost in Transplantation: Characterizing Racial Gaps in Physician Organ Offer Acceptance
Background. There are known racial disparities in the organ transplant allocation system in the United States. However, prior work has yet to establish if transplant center decisions on offer acceptance—the final step in the allocation process— contribute to these disparities. Objective To estimate racial differences in the acceptance of organ offers by transplant center physicians on behalf of their patients. Design Retrospective cohort analysis using data from the Scientific Registry of Transplant Recipients (SRTR) on patients who received an offer for a heart, liver, or lung transplant between January 1, 2010 and December 31, 2020. Setting Nationwide, waitlist-based. Patients 32,268 heart transplant candidates, 102,823 liver candidates, and 25,780 lung candidates, all aged 18 or older. Measurements 1) Association between offer acceptance and two race-based variables: candidate race and donor-candidate race match; 2) association between offer rejection and time to patient mortality. Results Black race was associated with significantly lower odds of offer acceptance for livers (OR=0.93, CI: 0.88-0.98) and lungs (OR=0.80, CI: 0.73-0.87). Donor-candidate race match was associated with significantly higher odds of offer acceptance for hearts (OR=1.11, CI: 1.06-1.16), livers (OR=1.10, CI: 1.06-1.13), and lungs (OR=1.13, CI: 1.07-1.19). Rejecting an offer was associated with lower survival times for all three organs (heart hazard ratio=1.16, CI: 1.09-1.23; liver HR=1.74, CI: 1.66-1.82; lung HR=1.21, CI: 1.15-1.28). Limitations Our study analyzed the observational SRTR dataset, which has known limitations. Conclusion Offer acceptance decisions are associated with inequity in the organ allocation system. Our findings demonstrate the additional barriers that Black patients face in accessing organ transplants and demonstrate the need for standardized practice, continuous distribution policies, and better organ procurement.
Open AccessLost in Transplantation: Characterizing Racial Gaps in Physician Organ Offer Acceptance
Background. There are known racial disparities in the organ transplant allocation system in the United States. However, prior work has yet to establish if transplant center decisions on offer acceptance—the final step in the allocation process— contribute to these disparities. Objective To estimate racial differences in the acceptance of organ offers by transplant center physicians on behalf of their patients. Design Retrospective cohort analysis using data from the Scientific Registry of Transplant Recipients (SRTR) on patients who received an offer for a heart, liver, or lung transplant between January 1, 2010 and December 31, 2020. Setting Nationwide, waitlist-based. Patients 32,268 heart transplant candidates, 102,823 liver candidates, and 25,780 lung candidates, all aged 18 or older. Measurements 1) Association between offer acceptance and two race-based variables: candidate race and donor-candidate race match; 2) association between offer rejection and time to patient mortality. Results Black race was associated with significantly lower odds of offer acceptance for livers (OR=0.93, CI: 0.88-0.98) and lungs (OR=0.80, CI: 0.73-0.87). Donor-candidate race match was associated with significantly higher odds of offer acceptance for hearts (OR=1.11, CI: 1.06-1.16), livers (OR=1.10, CI: 1.06-1.13), and lungs (OR=1.13, CI: 1.07-1.19). Rejecting an offer was associated with lower survival times for all three organs (heart hazard ratio=1.16, CI: 1.09-1.23; liver HR=1.74, CI: 1.66-1.82; lung HR=1.21, CI: 1.15-1.28). Limitations Our study analyzed the observational SRTR dataset, which has known limitations. Conclusion Offer acceptance decisions are associated with inequity in the organ allocation system. Our findings demonstrate the additional barriers that Black patients face in accessing organ transplants and demonstrate the need for standardized practice, continuous distribution policies, and better organ procurement.
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (1) , 12-13
Seeing through the Smoke: Clearing Up the Link between Donor Smoke Exposure and Lung Transplant Outcomes
- 1 January 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (1) , 12-13
Open AccessSeeing through the Smoke: Clearing Up the Link between Donor Smoke Exposure and Lung Transplant Outcomes